Ignite Creation Date:
2024-05-06 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05132218
Status:
RECRUITING
Last Update Posted:
2021-11-24
First Post:
2021-10-26
Brief Title:
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Sponsor:
Organization:
Peking University Cancer Hospital Institute
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
1 The patients tumor tissue sample before taking Ensatinib
2 The patients baseline blood sample within the first week before taking Ensantinib
3 Blood samples of patients 4-6 weeks after taking Ensatinib
4 Blood samples within 4 weeks after the patients disease progression
Enrollment Count:
180
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 80804 |
Who Masked List: